Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Desvenlafaxine administered as a salt in a sustained-release form · 1 trial · 3 indications
HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50. Change= 8 week adjusted mean HAM-D17 minus baseline adjusted mean HAM-D17
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR) | DRUG | DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks |
| Placebo | DRUG | Placebo, daily (QD), tablet form, treatment period up to 8 weeks |
Inclusion Criteria: * Peri- and postmenopausal women between the ages of 40 and 70 years, inclusive. * A primary diagnosis of MDD, single or recurrent episode, without psychotic features using the modified International Neuropsychiatric Interview (MINI). * Montgomery-Asberg Depression Rating Scale ...
Desvenlafaxine administered as a salt in a sustained-release form is an investigational small molecule being developed by Pfizer, Inc. (PFE) for depression. It is a sustained-release formulation of desvenlafaxine, the active metabolite of venlafaxine, and is also known as desvenlafaxine succinate sustained release (DVS SR).
Desvenlafaxine administered as a salt in a sustained-release form is being studied for the treatment of depression, including depressive disorder and major depressive disorder. Its clinical development has focused on peri- and postmenopausal women with depression, a population evaluated in its Phase 3 trial.
Desvenlafaxine administered as a salt in a sustained-release form acts as an inhibitor of SLC6A2 (norepinephrine transporter) and SLC6A4 (serotonin transporter). By inhibiting these transporters, it increases norepinephrine and serotonin levels in the brain, which is the proposed mechanism for its antidepressant activity.
Pfizer, Inc. (ticker: PFE) is the developer of desvenlafaxine administered as a salt in a sustained-release form. Pfizer conducted the Phase 3 clinical trial evaluating this sustained-release formulation in peri- and postmenopausal women with depression.
Desvenlafaxine administered as a salt in a sustained-release form is in Phase 3 clinical development. It is an investigational product and has not been approved by the FDA for any indication. The Phase 3 trial for this formulation has been completed.
Desvenlafaxine administered as a salt in a sustained-release form has been evaluated in one completed Phase 3 trial, NCT00369343, titled "Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women." The trial enrolled 381 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes, desvenlafaxine administered as a salt in a sustained-release form is also known as desvenlafaxine administered as a succinate salt in a sustained-release form, abbreviated DVS SR. The two names refer to the same investigational product developed by Pfizer for depression.